• NIFTY  
    11,596.90
    (-0.78%)
  • SENSEX  
    38,897.46
    ( -0.81%)
  • USDINR  
    68.48
    ( 0.14%)
  • GOLD  
    35,107.00
    ( 0.05%)
  • Hot Pursuit - Detailed News
Glenmark Pharma, Torrent Pharma rise after co-marketing pact for diabetes drug
11-Jul-19   14:03 Hrs IST

The announcement was made before trading hours today, 11 July 2019.

Meanwhile, S&P BSE Sensex was up 229.40 points or 0.59% at 38,786.44.

Glenmark Pharmaceuticals and Torrent Pharmaceuticals have entered into a non‐exclusive sub‐licensing agreement to co‐market Sodium Glucose Co‐Transporter‐2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.

Under the terms of the agreement, Glenmark Pharmaceuticals will receive an upfront payment, license fees and royalties for The non‐exclusive sub‐license rights from Torrent Pharmaceuticals. Glenmark Pharmaceuticals will manufacture and supply Remogliflozin while Torrent Pharmaceuticals will market the drug under its own trademark 'Zucator' in India.

Remogliflozin is indicated in the treatment of Type 2 Diabetes Mellitus in adults.

On a consolidated basis, Glenmark Pharmaceuticals' net profit rose 6.6% to Rs 161.66 crore on a 12.4% rise in net sales to Rs 2,526.08 crore in Q4 March 2019 over Q4 March 2018.

Meanwhile, Torrent Pharmaceuticals' consolidated net profit fell 37.7% to Rs 142 crore on a 9.4% increase in net sales to Rs 1,822 crore in Q4 March 2019 over Q4 March 2018.

Glenmark Pharmaceuticals (GPL) is a research‐driven, global, integrated pharmaceutical organization.

Torrent Pharmaceuticals is involved in niche marketing in India and has a presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.

Powered by Capital Market - Live News

Useful Links

Attention Investors
Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day.............issued in the interest of investors. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account                                    "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
Investors should be cautious of unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.BSE   http://www.bseindia.com/investors/tip-off-registration.aspx?expandable  NSE   https://www.nseindia.com/int_invest/dynacontent/any_portal.htm
All payments to Stock Broker shall be received from the market intermediaries/participants strictly by account payee crossed cheques / demand drafts or by way of direct credit into the bank account through electronic fund transfer, or any other mode permitted by the Reserve Bank of India. Stock Brokers shall not accept cash from their clients either directly or by way of cash deposit to the Bank Account of Stock Broker.
Group Companies Members of : BSE, NSE, MCX, MCX.SX, CDSL, NCDEX, Broking Services, Depository Services, Portfolio Management Services, Member Area IPO Distribution, Insurance Broking
BSE Clearing No.: 911 | SEBI Regn. No.: INZ000177531 (Cash/F&O) | NSE Clearing No.: 11858 | SEBI Regn. No. INZ000177531 (Cash/F&O/CDs) | MCX-SX Clearing No.: 11400 | SEBI Regn. No.: INZ000177531 (CDs) | CDSL DP ID: 30300 | SEBI Regn. No.: IN-DPCDSL-210-2003 | MCX SEBI Reg No.: INZ000032336 | MCX: 10665 | NCDEX: 00254 | NBFC RBI Regn. No.: 13.01851
© Copyright 2018 Ajmera Associates Ltd ( ISO 9001:2015 Certified )
Designed, Developed and Powered By CMOTS Infotech ( ISO 9001:2015 Certified )